LEISHMANIA DONOVANI: CD2 BIASED IMMUNE RESPONSE SKEWS THE SAG MEDIATED THERAPY FOR A PREDOMINANT TH1 RESPONSE IN EXPERIMENTAL INFECTION

S. Sinha¹, S. Bimal², S. Sundaram¹

¹Centre for Biotechnology, University of Allahabad, Allahabad, ²Division of Immunology, Rajendra Memorial Research Institute of Medical Sciences, Patna, India

We have evaluated the effect of combining CD2 with conventional antimonial (sb) therapy in protection in BALB/c mice infected with either drug sensitive or resistant strain of Leishmania donovani with 3x10⁷ parasites via-intra-cardiac route. Mice were treated with anti CD2 adjunct SAG sub-cutaneously twice a week for 4 weeks. Assessment for measurement of weight, spleen size, anti-Leishmania antibody titer, T cell and anti-leishmanial macrophage function was carried out day 0, 10, 22 and 34 post treatments. The combination therapy was shown boosting significant proportion of T cells to express CD25 compared to SAG monotherapy. Although, the level of IFN-c was not statistically different between combination vs monotherapy (p = 0.298) but CD2 treatment even alone significantly influenced IFN-c production than either SAG treatment (p = 0.045) or with CD2 adjunct SAG treatment (p = 0.005) in Ld-S strain as well as in Ld-R strain. The influence of CD2 adjunct treatment was also documented in anti-leishmanial functions in macrophages. Our results indicate that CD2, which can boost up a protective Th1 response, might also be beneficial to enable SAG to induce Macrophages to produce Leishmanicidal molecules and hence control the infection in clinical situation like Kala-azar. Drug resistance is the major impedance for disease control but the encouraging results obtained after infecting mice with resistant strain of the parasite strongly imply that this drug can be effective even in treating resistant cases of Kala-azar.